Payment overview · 2025
General Payments
$1,231.09
82 reported records · 19 companies
Healthcare provider profile · identity verified
Amanda J Mcgee, FNPC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MORGANTON, NC · NPI 1962492082
Verified facts
What the public records show
CMS Open Payments records show Amanda J Mcgee, FNPC received $1,231.09 in general payments during 2025 across 82 reported records.
Novo Nordisk Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.94 | 18.6% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $180.26 | 14.6% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $152.54 | 12.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.35 | 12.2% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.14 | 10.1% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $60.35 | 4.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.03 | 3.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.90 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.80 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.96 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.73 | 2.7% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.16 | 2.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.22 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.72 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.71 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.20 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.94 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.14 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.00 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,231.09 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $152.54 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.25 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $143.25 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $126.85 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.14 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.14 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $122.94 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.74 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.04 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.71 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.53 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $44.64 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.93 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.73 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $5.79 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $5.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
111 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 19 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 482 | 62 |
| Omeprazole | Omeprazole | 469 | 69 |
| Lisinopril | Lisinopril | 406 | 56 |
| Gabapentin | Gabapentin | 350 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 52 |
| Potassium Chloride | Potassium Chloride | 326 | 48 |
| Furosemide | Furosemide | 281 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 40 |
| Trazodone Hcl | Trazodone Hcl | 273 | 38 |
| Metformin Hcl | Metformin Hcl | 245 | 35 |
| Sertraline Hcl | Sertraline Hcl | 245 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 32 |
| Donepezil Hcl | Donepezil Hcl | 208 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 195 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 188 | 24 |
| Buspirone Hcl | Buspirone Hcl | 183 | 31 |
| Meloxicam | Meloxicam | 183 | 34 |
| Valsartan | Valsartan | 183 | 32 |
| Celecoxib | Celecoxib | 161 | 26 |
| Montelukast Sodium | Montelukast Sodium | 160 | 22 |
| Losartan Potassium | Losartan Potassium | 154 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 146 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 18 |
| Eliquis | Apixaban | 135 | 19 |
| Prednisone | Prednisone | 135 | 69 |
| Famotidine | Famotidine | 134 | 19 |
| Risperidone | Risperidone | 133 | suppressed |
| Alprazolam | Alprazolam | 128 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 14 |
| Simvastatin | Simvastatin | 116 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 19 |
| Atenolol | Atenolol | 111 | 17 |
| Linzess | Linaclotide | 111 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 15 |
| Allopurinol | Allopurinol | 107 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 105 | 15 |
| Clonazepam | Clonazepam | 102 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 14 |
| Tramadol Hcl | Tramadol Hcl | 99 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 15 |
| Lorazepam | Lorazepam | 95 | 21 |
| Estradiol | Estradiol | 94 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 12 |
| Ondansetron Odt | Ondansetron | 90 | 33 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 89 | 12 |
| Metformin Hcl Er | Metformin Hcl | 88 | 13 |
| Aripiprazole | Aripiprazole | 84 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 80 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 12 |
| Pregabalin | Pregabalin | 77 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 14 |
| Jardiance | Empagliflozin | 70 | 15 |
| Carvedilol | Carvedilol | 69 | 13 |
| Memantine Hcl | Memantine Hcl | 66 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Finasteride | Finasteride | 63 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 62 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 60 | suppressed |
| Glipizide | Glipizide | 60 | suppressed |
| Topiramate | Topiramate | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | suppressed |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Azithromycin | Azithromycin | 55 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 44 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Nystatin | Nystatin | 50 | 15 |
| Ozempic | Semaglutide | 50 | suppressed |
| Baclofen | Baclofen | 48 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | suppressed |
| Lactulose | Lactulose | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 41 |
| Temazepam | Temazepam | 40 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Austedo | Deutetrabenazine | 29 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Constulose | Lactulose | 27 | suppressed |
| Nyamyc | Nystatin | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Febuxostat | Febuxostat | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Caplyta | Lumateperone Tosylate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,231.09 · 82 records | Novo Nordisk Inc | AIRSUPRA, AJOVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, ELIQUIS, EVENITY, FANAPT, FARXIGA, IBSRELA, INGREZZA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error